FIELD: pharmaceutics; medicine.
SUBSTANCE: first object is the use of an antibody or its antigen-binding fragment for the production of a drug for reduction in the frequency of headache attacks in a patient suffering from chronic or episodic migraine. In this case, the antibody or its antigen-binding fragment locks, inhibits, suppresses, or weakens a path with participation of calcitonin gene-related peptide (hereinafter – CGRP). Before the injection of the antibody or its antigen-binding fragment, it is known that the patient has allodynia and/or hyperalgesia during the acute phase of migraine, but not during the phase between migraine attacks. The second object is a method for the reduction in the frequency of migraine attacks in the above-mentioned patient, including the injection of the above-mentioned antibody or its antigen-binding fragment.
EFFECT: reduction in the frequency of headache attacks in a patient in the injection of an antibody or its antigen-binding fragment that lock, inhibit, suppress or weaken a path with the participation of CGRP, where, before the injection, it was determined or known that the patient has allodynia and/or hyperalgesia during the acute phase of migraine, but not during the phase between migraine attacks.
45 cl, 24 dwg, 6 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
EphA4 ANTIBODY | 2016 |
|
RU2719158C2 |
ANTIBODY AGAINST BETA-AMYLOID, ANTIGEN-BINDING FRAGMENT OF SAID ANTIBODY, AND APPLICATION THEREOF | 2019 |
|
RU2777844C1 |
EphA4 ANTIBODY | 2020 |
|
RU2816371C2 |
RGMa BINDING PROTEIN AND ITS USE | 2016 |
|
RU2809500C2 |
MONOCLONAL ANTIBODIES TO ALPHA-SYNUCLEIN FOR PREVENTING TAU-PROTEIN AGGREGATION | 2017 |
|
RU2760334C2 |
ANTIBODIES WHICH BIND TO SORTILIN AND INHIBIT THE BINDING OF PROGRANULIN | 2016 |
|
RU2735639C2 |
ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
MONOVALENT ANTIBODIES TO PROPERDIN AND FRAGMENTS OF ANTIBODIES | 2018 |
|
RU2790103C2 |
ANTIBODIES AGAINST HLA-G, COMPOSITIONS CONTAINING ANTIBODIES AGAINST HLA-G, AND METHODS OF USE OF ANTIBODIES AGAINST HLA-G | 2019 |
|
RU2810326C2 |
Authors
Dates
2022-04-14—Published
2018-03-01—Filed